EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Open Access · CC BY 4.0

Treatment of hidradenitis suppurativa with adalimumab in the PIONEER I and II randomized controlled trials reduced indices of systemic inflammation, recognized risk factors for cardiovascular disease

Niamh Kearney iD, Xin Chen iD, Yingtao Bi iD, Kinjal Hew iD, Kathleen M Smith iD, Brian Kirby iD

Clinical and Experimental Dermatology · 2025

DOI: 10.1093/ced/llae324 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical and Experimental Dermatology, 2025. Verfasst von Niamh Kearney und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, St Vincent's University Hospital Dublin, Ireland. Hauptthemen laut MEDLINE: Adalimumab, Hidradenitis Suppurativa, Anti-Inflammatory Agents, Cardiovascular Diseases. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AbbVie, City of Dublin Skin, Cancer Hospital Charity.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hidradenitis suppurativa (HS) is associated with increased cardiovascular disease (CVD) risk. Systemic immune inflammation index (SII), neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR) and monocyte/lymphocyte ratio (MLR) are biomarkers of systemic inflammation and CVD. One small study identified a lower NLR and PLR in patients treated with adalimumab (ADA).

Objectives

To assess changes in SII, NLR, PLR and MLR in a larger cohort and to evaluate their association with disease severity and treatment response.

Methods

This was a post hoc analysis of PIONEER I (ClinicalTrials.gov ID: NCT01468207) and PIONEER II (ClinicalTrials.gov ID: NCT01468233), two phase III randomized placebo-controlled clinical trials of ADA for HS. SII, NLR, PLR and MLR were log10-transformed and a linear mixed model was used to estimate the treatment effect.

Results

SII, NLR, PLR and MLR decreased from baseline levels with ADA treatment by week 12, when the primary response endpoint was assessed. Significant changes first appeared at week 4 and were maintained to week 36. In contrast, no significant changes were observed in placebo-treated patients. In patients re-randomized at week 12 from placebo to ADA, SII, NLR, PLR and MLR also reduced within 4 weeks. In patients re-randomized from ADA to placebo, these biomarkers returned to baseline by week 36. In addition, SII, NLR and PLR correlated with draining fistula count (r = 0.26–0.43, P < 0.001). ADA nonresponders in PIONEER I had a higher SII, NLR and PLR at baseline and week 12, but this change did not achieve statistical significance when draining fistulae were adjusted for.

Conclusions

Treatment of patients with HS with ADA resulted in rapid sustained reduction in systemic inflammation, measured by the biomarkers SII, NLR, PLR and MLR, which correlate with CVD risk. SII, NLR and PLR may predict ADA response, although this may be dependent on their interaction with the number of draining fistulae.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdalimumabHidradenitis SuppurativaAnti-Inflammatory AgentsCardiovascular DiseasesInflammationHumansMaleFemaleAdultMiddle AgedBiomarkersSeverity of Illness IndexNeutrophilsHeart Disease Risk FactorsTreatment Outcome

Substanzen

AdalimumabAnti-Inflammatory AgentsBiomarkers

Autor:innen und Institutionen

  • Department of Dermatology, St Vincent's University Hospital Dublin, Ireland.
  • School of Medicine, University College Dublin, Ireland.
  • AbbVie Inc., North Chicago, IL, USA.
  • Charles Institute of Dermatology, University College Dublin, Ireland.

ORCID-Profile: Niamh Kearney, Xin Chen, Yingtao Bi, Kinjal Hew, Kathleen M Smith, Brian Kirby

Förderung

  • AbbVie
  • City of Dublin Skin
  • Cancer Hospital Charity

Zitieren

APA

Kearney, N., Chen, X., Bi, Y., Hew, K., Smith, K. M., & Kirby, B. (2025). Treatment of hidradenitis suppurativa with adalimumab in the PIONEER I and II randomized controlled trials reduced indices of systemic inflammation, recognized risk factors for cardiovascular disease. Clinical and Experimental Dermatology. https://doi.org/10.1093/ced/llae324

Vancouver

Kearney N, Chen X, Bi Y, Hew K, Smith KM, Kirby B. Treatment of hidradenitis suppurativa with adalimumab in the PIONEER I and II randomized controlled trials reduced indices of systemic inflammation, recognized risk factors for cardiovascular disease. Clinical and Experimental Dermatology. 2025. doi:10.1093/ced/llae324

BibTeX
@article{Kearney2025,
  author = {Kearney, Niamh and Chen, Xin and Bi, Yingtao and Hew, Kinjal and Smith, Kathleen M and Kirby, Brian},
  title = {Treatment of hidradenitis suppurativa with adalimumab in the PIONEER I and II randomized controlled trials reduced indices of systemic inflammation, recognized risk factors for cardiovascular disease},
  journal = {Clinical and Experimental Dermatology},
  year = {2025},
  doi = {10.1093/ced/llae324}
}
Kostenlos starten →